Compugen Ltd. (CGEN:NASDAQ) closed at $2.03 on November 3, 2026, up 2.54% on the day. The stock trades 37.3% below its 52-week high of $3.24 and 42.0% above its 52-week low of $1.43. Over the past year, it gained 14.5%. Compugen Ltd. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 31, 2025, CGEN closed higher on 116 days (46%). Its best day was March 2, 2026 (+24.31%) and its worst was March 3, 2026 (-11.11%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 1 time.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Find more stocks like CGEN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.